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Background: Coronary heart disease (CHD) is a common medical problem in general practice. Due to its chronic
character, shared care of the patient between general practitioner (GP) and cardiologist (C) is required. In order to
improve the cooperation between both medical specialists for patients with CHD, a local treatment pathway was
developed. The objective of this study was first to evaluate GPs’ opinions regarding the pathway and its practical
implications, and secondly to suggest a theoretical framework of the findings by feeding the identified key factors
influencing the pathway implementation into a multi-dimensional model.
Methods: The evaluation of the pathway was conducted in a qualitative design on a sample of 12 pathway
developers (8 GPs and 4 cardiologists) and 4 pathway users (GPs). Face-to face interviews, which were aligned with
previously conducted studies of the department and assumptions of the theory of planned behaviour (TPB), were
performed following a semi-structured interview guideline. These were audio-taped, transcribed verbatim, coded,
and analyzed according to the standards of qualitative content analysis.
Results: We identified 10 frequently mentioned key factors having an impact on the implementation success of the
CHD treatment pathway. We thereby differentiated between pathway related (pathway content, effort, individual
flexibility, ownership), behaviour related (previous behaviour, support), interaction related (patient, shared care/
colleagues), and system related factors (context, health care system). The overall evaluation of the CHD pathway
was positive, but did not automatically lead to a change of clinical behaviour as some GPs felt to have already
acted as the pathway recommends.
Conclusions: By providing an account of our experience creating and implementing an intersectoral care pathway
for CHD, this study contributes to our knowledge of factors that may influence physicians’ decisions regarding the
use of a local treatment pathway. An improved adaptation of the pathway in daily practice might be best achieved
by a combined implementation strategy addressing internal and external factors. A simple, direct adaptation
regards the design of the pathway material (e.g. layout, PC version), or the embedding of the pathway in another
programme, like a Disease Management Programme (DMP). In addition to these practical implications, we propose
a theoretical framework to understand the key factors’ influence on the pathway implementation, with the
identified factors along the microlevel (pathway related factors), the mesolevel (interaction related factors), and
system- related factors along the macrolevel.
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Despite the declining mortality of patients in recent
years with coronary heart disease (CHD) in Western
countries [1,2], CHD remains the leading cause of mor-
bidity and mortality in adults worldwide [3]. In the Uni-
ted States, about 7.0 % (women) to 9.1 % (men) of the
general population are affected by CHD [4]. Similar
prevalence rates (women: 6.5 %, men: 9.2 %) have been
found in Germany [5]. Most patients with CHD need
lifelong, continuous, complex medical care, which is ex-
tremely costly to the healthcare system [6].
In this context, an important role is attached to the
shared care of patients with CHD by the general practi-
tioner (GP) and the cardiologist. Better coordination and
communication between GP and medical specialist pro-
mises optimized medical treatment along with increased
cost-effectiveness in primary care [7-9]. Improving the co-
operation between different health care professionals and
providing optimal evidence-based medical care for
patients are the main objectives of clinical guidelines [10].
For CHD, it was demonstrated that non-adherence to
medical recommendations is associated with a broad
range of adverse outcomes in patients [11]. Despite the
high scientific quality of most guidelines and their wide
promulgation, their actual impact on clinical practice and
quality of care is limited [12-15]. Numerous international
studies have shown that effective and lasting behaviour
change of health care professionals is difficult to achieve
and is influenced by multiple factors [16-18]. Although
guidelines may be seen as necessary to provide valid
recommendations, they are insufficient in ensuring
evidence-based decision-making [19]. In this context, the
use of clinical pathways as one approach to facilitate the
adaption of research findings in daily practice is import-
ant. Clinical pathways are multidisciplinary, locally trans-
latable, and involve a stepwise procedure, determined
timeframes, and standardized care for a specific clinical
problem [20]. Even though the implementation of clinical
pathways faces similar problems as the implementation of
guidelines [21,22], some authors [19,23,24] expect treat-
ment pathways to raise implementation chances by adapt-
ing the guideline recommendations to local conditions
and thereby referring more to physicians’ work reality.
However, the effect of local treatment pathways is contro-
versial, as Salegy and colleagues [25] rarely found an im-
plementation benefit by the local adaption. Additionally,
the local adaption was associated with higher costs com-
pared to national guidelines. Nevertheless, the develop-
ment and use of a local pathway might be appropriate in
situations where an additional advantage is expected by its
use. This might be of importance if system related factors
require local adjustments [25].
To date, most experience with treatment pathways is
gained in countries with a Beveridge type of health caresystem, characterized by a strong governmental influ-
ence. In countries like Germany, where a Bismarck type
of health care system is established [26], the implemen-
tation of shared care pathways poses a special challenge
as they are less regulated by institutional standards.
Patients have universal medical access with only a very
limited gate-keeping role of the GP. Due to the system
structure, competition between medical professionals in
the ambulatory sector (primary and secondary care) hin-
ders cooperation. Thus, despite a greater need for coord-
ination, the establishment of shared care pathways is
paradoxically much more difficult to achieve in Bismarck
types of health care systems. By developing and imple-
menting a shared care pathway for patients with CHD in
a Bismarck type system, we intended to close this gap
and contribute a new aspect to existing research primar-
ily made in the Beveridge type of health care systems.
Within this context of developing and evaluating a local
CHD pathway we pursued two objectives in this study. On
the one hand we aimed to evaluate GPs’ opinion regarding
the pathway and give practical implications for clinical
practice that derived from this evaluation. On the other
hand we strived to abstract our findings by putting the
identified key factors influencing the pathway implemen-
tation into a multi-dimensional model.Methods
Development and description of the CHD pathway
In 2008, GPs and cardiologists from the Marburg region,
Germany, were invited by the Department of General
Practice at the University of Marburg to jointly develop
a local treatment pathway for patients with CHD. By in-
volving end-users in the pathway development and thus
considering their experience and expertise of daily prac-
tice, we realized a bottom-up approach [27]. It was
assumed that a cooperatively developed local consensus
with the collaboration of GPs and cardiologists would
improve GPs’ and cardiologists’ acceptance and adher-
ence to the corresponding guideline recommendations
for the handling of CHD patients in primary care [19].
The development of the pathway was based on current
regional [28] and national care guidelines[29]. Within
small working groups moderated by members of the de-
partment, plans for monitoring visits, relevant drugs,
and documentation forms were developed and brought
to a consensus with all participants. To support the im-
plementation of the pathway in daily practice, we pro-
vided the physicians with both a laminated pocket
version of the pathway guidelines covering drugs and
monitoring visits, and patient treatment logs to list
medication and monitoring visits for every patient. An
overview of the pocket version of the pathway is given in
Additional file 1.
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Our qualitative study was part of a larger feasibility study
[30] with 18 GPs in three study arms (8 pathway develo-
pers, 6 pathway users, 6 control group) and 290 consecu-
tively recruited patients with CHD. This larger study was
on the development and evaluation of a local CHD treat-
ment pathway using quantitative and qualitative compo-
nents (mixed methods study). An overview of the
intended larger feasibility study design is given in Figure 1.
In brief, the larger project aimed to improve the shared
care of patients with CHD by GPs and cardiologists. The
quantitative study investigated physicians’ adherence to
pathway recommendations regarding the prescription of
drugs and the referrals to the cardiologist, and its impact
on patient variables such as satisfaction with the treatment
and health-related quality of life. The analysis of the quan-
titative results and its relation to the qualitative data (tri-
angulation) is in progress and will be reported soon. To
gain further insight into GPs’ opinion regarding the path-
way and the factors influencing GPs’ decision to (not) im-
plement the CHD pathway, we conducted this qualitative
study in the middle of the feasibility study so that physi-
cians’ experience with the pathway could be ascertained.
Face-to-face interviews were undertaken during February
and March 2010 in the physicians’ practices by one of the
authors (LK) who was not involved in the development of
the pathway.
In our study we aimed not only to report the results of












Consecutive recruitment of CH
Quantitative
Figure 1 Study design of the larger feasibility study.identify the latent pattern of the data. According to San-
delowski and Barroso, this more explanatory than ex-
ploratory interpretation of the qualitative data can be
categorized as thematic/conceptual as we provide a the-
oretical framework of our findings [31]. The results
gained in our study, like those of the quantitative study,
may inform the planning and conducting of an subse-
quent randomised controlled trial (RCT) evaluating the
efficacy of the CHD pathway [30].
GPs and patients were informed in detail about the
study and all gave their written consent to the study par-
ticipation. Ethical approval for the study was obtained
from the Ethics Committee of the Faculty of Medicine at
the Phillips University of Marburg, Germany.
Participants and recruitment procedures
Within the context of the feasibility study, we asked all 12
pathway developers (8 GPs and 4 cardiologists) and the 6
pathway users, familiar with the pathway recommenda-
tions, to participate in our qualitative evaluation study.
Thus, by selecting respondents that were most likely to
yield useful information about the key factors influencing
the pathway implementation, we used a purposeful sam-
pling strategy [32] and considered our sample size as ap-
propriate to achieve saturation [33]. As the GPs of the
control group did not know the pathway, we did not in-
clude them in the study. All physicians from the interven-
tion groups were located in the Marburg region,
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Table 1 Demographics of the study sample: GPs and
cardiologists (n = 16)





≤ 40 1 (6.3)
41 to 50 9 (56.3)
51 to 60 5 (31.3)
> 60 1 (6.3)
Established since (years)
≤ 10 10 (62.5)
11 to 20 1 (6.3)
> 21 5 (31.3)
Characteristic of the practice
Single practice 5 (31.3)
Group practice 11 (68.8)
Practice location
< 5000 5 (31.3)
5000 to 20.000 2 (12.5)
20.000 to 100.000 9 (56.3)
Status
Full time 15 (93.8)
Part time 1 (6.3)
Agreement with the treatment pathway
Strong agreement 14 (87.5)
Average agreement 2 (12.5)
a Percentages may not add up to 100 % due to rounding.
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Phillips University of Marburg, Germany. The GPs from
the control group were located in a neighbouring town.
Data collection
The interviews were based on a semi-structured inter-
view guideline covering the attitude towards the devel-
oped pathway and medical innovations such as
treatment pathways and guidelines in general, key fac-
tors that influenced the implementation of the CHD
pathway in a negative or positive way, and suggestions of
improvement and behaviour changes in consequence of
the pathway. The interview guideline was developed
jointly by two of the authors (LK, NDB) and was aligned
with previously conducted studies from our department
on changes of professional behaviour [34,35] and the
components of the theory of planned behaviour (TPB)
[36]. Interview participants were assured that their
responses would remain confidential and anonymous.
Data analysis
Interviews were audio-taped and transcribed verbatim.
The accuracy of transcripts was checked prior to being
transferred to the computer software program Maxqda
2007 [37], which assisted data handling. Based on the
interview guideline, a thematic coding frame for the ana-
lysis of the interviews’ content was developed by the
authors (LK and KS). The first three interviews were
coded and then the evaluation of the coding frame was
discussed. Within the analysis process no further cat-
egories emerged, so we considered theme saturation as
achieved. Transcripts were coded separately by LK and
KS and then checked for consistency. The data analysis
and interpretation followed the standards of qualitative
content analysis [38]. The translation of the quotes from




Twelve pathway developers (8 GPs, 4 cardiologists) and
four pathway users consented to conducting face-to-face
interviews. The reason for non-participation of 2 GPs in
the user group was a lack of time. The majority of the
interviewees were male (75 %), between 41 and 50 years
of age (56 %), and employed in full-time practice (94 %).
Most of the interviewed GPs and cardiologists (75 %)
strongly agreed with the pathway. Further characteristics
of the participants are summarized in Table 1.
Key factors influencing the (non-)implementation of the
treatment pathway
As shown in Table 2, we summarized our codings sys-
tematically in subordinated key factors and assignedthem to a pathway-related (pathway content, effort, in-
dividual flexibility, ownership), behaviour-related (previ-
ous behaviour, support), interaction-related (patients,
shared care/colleagues) or system-related main category
(context, health care system). In total, we identified
10 key factors influencing the implementation of the
pathway.
As this study was undertaken to gain additional insight
into the relevant key determinants for implementation,
we focused a cross-case analysis on the identification of
general factors and were less interested in interindividual
differences.Pathway related factors
Pathway content
The first major theme in this category dealt with the
pathway content. Many of the participating GPs and car-
diologists (C) considered the CHD pathway as a useful
and high quality treatment aid.
Table 2 Classification of the key factors influencing the pathway implementation














• Assessment of guidelines
• Application area
• “Cookbook medicine” vs. individuality























• Disease Management Program (DMP)
Context System
• Bureaucracy
• Health care system
Health care
system
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framework of how to interact with certain patients,
so that it is clear for everybody. I think it’s a
reasonable thing.” [C1]
“I think it’s actually useful to have such an aid. It
improves your awareness for things you should keep
an eye on. To my delight, the number of beta
blockers was reduced and more certainty was
provided regarding the sequence of cardiological
consultations.” [GP2]
Effort
The effort created by the implementation of the pathway
in daily practice was perceived as controversial by the
interviewees. While the case record form (CRF) docu-
mentation for the evaluative study was assessed as time
consuming, the application of the pathway in practice
was rated as time saving, or no difference was
recognized.
“It was time consuming to somehow record
[the patients’ medication history]. The second time
around it was no problem because in most
cases nothing had changed. You could copy
[the information] or just refer to thefirst record. Integrating [the information] is not a
problem now, unlike the first time.” [GP6]
“I would say that [the pathway] certainly saves
time, [especially] for colleagues who haven’t
followed [the pathway’s recommendations] or
have yet to really put the drug therapy into
practice.” [GP1]
Individual flexibility
A relevant issue for the participating physicians was the
balance between ‘cookbook medicine’ by a high adherence
to the pathway’s recommendations and an individual treat-
ment of the patient. On the one hand, participants appre-
ciated the standardised treatment guideline, on the other
hand, they emphasized the consideration of intuition and
experience in the consultation.
“It is indeed like cookbook medicine, but on the
other hand, it makes one feel safer. And I think
that every one of us has a certain plan of how to
proceed for every clinical situation. And those
[plans] could be standardized. Then you can
say ‘Ok, we consistently proceed according
to this model, to this scheme.’ I think this is
good.” [GP7]
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am the one who decides based on my twenty years of
experience in cardiology. I do not want the pathway to
tell me what I have to do. Guidelines are only guide rails
within which you can act.” [C1]
Ownership
The participation in the development of the pathway
was an important factor for the physician’s evaluation of
the CHD treatment tool. Overall, the participation
resulted in a positive evaluation, even though conces-
sions had to be made.
“Our behaviour informed the pathway, like always. I
support [the pathway]; we worked on [its
development] for a long time. It was extensively
discussed before everybody could agree on its final
version. So I perceived [the pathway development] as
positive.” [C2]
“You are not bound to a guideline that was imposed
from above, but in whose development we took part,
and which we could influence. This is what makes it
good. If you contribute to such a thing, then it is
something you support. My ideas are included and
the way I think you should act. And, therefore, I am
totally in support of it.” [GP1]
“We could not enforce [the frequency of cholesterol
measurement]. When you make decisions as a group
you have to swallow some bitter pills.” [C3]
Behaviour-related factors
Previous behaviour
The appraisal of their own behaviour in the past was an
important factor for physicians’ willingness to imple-
ment the pathway. Many interviewees felt that they had
treated their patients with CHD according to the path-
way recommendations during previous visits.
“[Our behaviour] has not changed a lot. We have not
invented something new, but have, in principle,
implemented the guidelines.” [GP5]
“Actually, I acted like I always did: the patients came
in regular intervals, we talked about the disease, we
talked about incidents, we talked about the
cardiological report, and we checked the laboratory
parameters and drugs.” [GP6]
Support/Reminders
The participating GPs expressed a desire to integrate the
pathway recommendations into practice software. A PC
integration was perceived as facilitating the embeddingof the pathway in daily practice, e.g., the schedule for
monitoring visits. Concerning the need for regular re-
fresher meetings, the physicians had heterogeneous opi-
nions: On the one hand the knowledge update was
appreciated; on the other hand regular meetings were
seen as too time-consuming or simply unnecessary.
“Of course we would keep recommendations in mind
with regular training sessions, but we already have so
many continuing medical education (CME) events. So
it is not necessary.” [GP3]
“I think it’s reasonable to have regular trainings so
that it becomes second nature [to us doctors]. I think
this is very important.” [GP1]
Interaction-related factors
Patient
Patients’ acceptance of and compliance with the pathway
recommendations were rated high by the interviewees if
the pathway recommendations were thoroughly
explained. Furthermore, the participating physicians
reported that knowledge of the patient’s background,
e.g., medical history and psychosocial conditions, may in-
fluence the application of the pathway. This can be
reflected in either patient related assumptions or routine
actions in the consultation.
“And for the patient it [the pathway] is actually better.
He stays more compliant because he knows it is not
back and forth but a routine program that he gets
every time. This makes the patients feel safer.” [GP8]
“Of course we act according to the disorders and the
risk profile, but we know the patients from their
domestic conditions and whether they comply or not.
And in these cases I would vary [the treatment].”
[GP9]
“Being aware gets lost sometimes, especially when you
have had patients for years or take over a practice and
there are listed diagnoses and drugs, so you do not
always question everything, you just overlook things.”
[GP2]
Shared care/Colleagues
The cooperation between GPs and cardiologists was
appreciated by both sides. Apart from smaller disagree-
ments concerning coordination responsibility for the
CHD patients, or adherence to the pathway advice, the
collaboration was described as positive.
“We actually understood it as the treatment pathway
helps us to do our job, and that one part of that -
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primary care treatment. If we collaborate with
competent GPs, we already tend to tell our patients
that they have a competent GP to whom they should
primarily turn to, e.g., when deterioration
happens.” [C3]
“No problem now, [the cooperation] has improved
considerably. The cardiologists do not make it their
responsibility to schedule monitoring visits, instead
leaving it more to the GP`s discretion. [Cardiologists]
complained that many [patients] come to unnecessary




By integrating the pathway into a larger geographic, such
as nationwide or organizational contexts, e.g., a medical
association, the interviewed physicians expected an
increased implementation success of the tool. The over-
lap between the pathway and the German CHD Disease
Management Program (DMP) as systematic treatment
program for chronically ill people [6,39] was seen as an
impeding factor for the pathway implementation in cases
of differing recommendations.
“But I think that one can and should implement [the
pathway] at the health care system level. One could,
for example do [the pathway implementation] with
our medical association and raise it to another level.”
[C2]
“Because we are bound by contract to the DMP, we
are obligated to act correspondingly. Even if we
found the treatment pathway more reasonable,
we are forced to implement the DMP. Sanctions are
partially imposed if you do not participate in the
DMP.” [GP7]
Health care system
Participants perceived the actual demands of the
German health care system as influencing the imple-
mentation of the CHD pathway. Due to competing
tasks in daily practice, the pathway would be at
risk of being forgotten. The GPs named their small
gate-keeping influence in the German health care
system as influencing factors for appointments with
medical specialists as patients have free access to
specialised care.
“We have so many fires burning at the moment, so
many contracts, special regulations and treatment
plans, DMP situations and such, that we partlylose the big picture. That makes it difficult for
us.” [GP7]
“Thus, there is so much to work on at the moment. I
think that is the main reason for not optimally
meeting the requirements of every patient.” [GP9]
“I actually see another essential problem in, such is it
here, we have free choice of care and many people go
to secondary care on their own decision.” [GP7]
Discussion
Main findings
Our study complements the understanding of potential
facilitators and barriers to be considered in planning the
implementation of innovative tools like the CHD path-
way and is in line with the findings of other international
studies [10,16,17,40].
Concerning the treatment pathway itself, we first
assessed the pathway content, the participation in the
pathway development/ownership, the individual flexibil-
ity, and the related effort as relevant aspects for the im-
plementation. The overall evaluation of the pathway
recommendations was positive and required no add-
itional effort by some of the GPs. Referring to the path-
way development, which was appreciated by the
physicians, a study by Grimshaw and colleagues showed
that the participation in developing a guideline could en-
hance the compliance in physicians by about 32 %,
whereas it was 22 % for non-developers [12]. Addition-
ally, the active involvement of end-users in the local
adaptation of clinical guidelines was found to lead to
lead to significant changes in practice through a sense of
ownership [19,41]. As seen in other studies, the inter-
viewed physicians perceived the ambivalence between
the facilitation by standardized guidance and the restric-
tion of their own medical autonomy as relevant [42-44].
In addition to the aspects related to the pathway, we
identified further relevant factors. On a behaviour-
related level we identified previous behaviour and sup-
port as important factors for pathway implementation.
Located on an interactional level and consistent to other
research, the patients’ acceptance of the pathway and the
physicians’ cooperation with their colleagues were
assessed as important components for the implementa-
tion of the pathway [45]. Patients’ acceptance of the
recommendations of the pathway was rated high by the
physicians. In accordance with a study by Summerskill
and Pope, our findings suggest that a physician’s know-
ledge of a patient’s background is an influencing factor
for the successful implementation of medical innova-
tions [45]. As a result, this could lead to assumptions,
which then exclude or include specific treatments for
certain patients, for example those with a certain risk
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background may also result in routine actions in the
consultation, which may lead to overlooking other
indications.
Finally, on a system level, an effective use of the CHD
pathway depends on both the health care system and the
context in which the medical implementation occurs.
Considering the impact of contextual factors for the
successful implementation of medical innovations is an
aspect also mentioned by other authors [40,46]. We
aimed to raise the pathway’s implementation success by
realizing a bottom-up approach and local attuning in the
development and implementation of the CHD pathway;
this can be seen in other studies where the application
of a bottom-up strategy led to improvements in out-
comes of care [47,48]. In contrast to these findings, our
results suggest that physicians also attach importance to
enabling features that can be centrally provided, such as
embedding the pathway in a DMP, or providing regular
trainings.
Practical implications
Even though the overall evaluation of the pathway
recommendations was positive, this appreciation did not
automatically lead to a behaviour change as some physi-
cians reported to have already been treating their
patients as the pathway recommends. According to the
theory of planned behaviour (TPB) [36], attitude is an
important factor for behaviour change, but our study
reveals that on its own it is an insufficient precondition
for a lasting implementation of the pathway. Thus, to
enhance the adaptation of the pathway in daily practice,
an appropriate implementation strategy is required. As
the effectiveness of single measures depends on the con-
text, the professional group or the disease [49], an indi-
vidually designed strategy that includes different
components is thought to be most promising [50]. A
first step to raising the awareness of the physicians
might be to modify the layout of the laminated pocket
version as a pathway-related factor. Another approach
facing interactional and behavioural factors is to estab-
lish regular quality circles where the appropriate use of
the pathway is discussed and supervised. Some of the
interviewed physicians felt that their individual treat-
ment flexibility was limited by the pathway as it pro-
poses a structured treatment plan. Thus, to prevent a
complete rejection of the pathway, it might make sense
to broaden coarsen the recommendations and give
benchmarks instead of detailed instructions. Being aware
that GPs’ perception of conformity does not necessarily
correspond to real facts, further research must be under-
taken to investigate a supposed perception-reality gap.
As mentioned by the physicians, the implementation
of the pathway would be eased by its integration into PCsoftware and thus simplify and standardize recall possi-
bilities. Another factor influencing the pathway imple-
mentation are competing recommendations of the
pathway and the German DMP, as the DMP includes
mostly similar, but sometimes aberrant recommenda-
tions and different timetables. A possible practical impli-
cation would be to embed the pathway
recommendations directly in a DMP, or taking the DMP
recommendations into account during the process of
pathway development.
Theoretical framework
In addition to reporting our findings and giving some
practical implications, we aimed to abstract our results
and give a theoretical framework (see Figure 2) based on
the main categories mentioned in Table 1.
We thereby considered two dimensions: temporal se-
quence and content. We assumed that the key factors
influencing the implementation of the CHD treatment
pathway can be classified according to their impact in
the pre-intervention, e.g., previous behaviour, the
present-intervention, e.g., pathway material, or the post-
intervention period, e.g., support. Referring to the Eco-
logical System Theory by Bronfenbrenner [51] and based
on a similar model developed in our department [35],
we differentiated between several levels of the health
care sector, namely the micro-, meso- and macrolevel.
Additionally, our model shows similarities with the con-
ceptual framework proposed by Sorensen and collea-
gues, which addresses the social context (including
individual, interpersonal, organizational and neighbour-
hood/community factors) as essential for behaviour
change [52]. Thus, the pathway-related factors were
arranged along the microlevel, the interaction-related
factors along the mesolevel, and the system-related fac-
tors along the macrolevel. Due to their primary time-
related impact, the behaviour-related factors were
excluded from this content-related classification within
the model.
We do not claim completeness of the aforementioned
factors or categories, nor do we provide an algorithm of
how the presence or absence of the reported key factors
attributes to the relative implementation success of the
pathway. Our interest was to propose a theoretical
framework that might serve as background for further
implementation research.
Study limitations
As a result of the qualitative study design and the small
study sample, the representativeness of the data may be
limited. In addition, the selection bias caused by the fact
that only motivated and interested physicians partici-
pated in the study may influence the representativeness
of the results. A possible bias by social desirability in the
Figure 2 Multi-dimensional model of implementation.
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due to the meaningful results and conclusions gained in
a Bismarck type of health care system, we presume the
chosen method to be appropriate for our research ques-
tion [53-55], which is aimed more at involved compo-
nents than defined outcome measures [56].
Another limitation concerns the proposed multi-
dimensional model. The distinction between the time-
and level-related categories should not be seen as static.
The model is a draft with flexible confines between the
singular categories and has to be proven in further re-
search. For example, due to its actual impact, we related
the pathway development to a present point in time;
putting this factor in the past would have been another
possibility. We did not investigate possible differences in
the response patterns of pathway developers and pure
users, or GPs and cardiologists, while the research ques-
tion focused on the identification of general factors in-
fluencing the pathway implementation rather than on
interindividual differences.
As our research dealt primarily with external imple-
mentation factors and final outcomes, the role of under-
lying psychological and interactional processes will need
to be investigated in future studies. In addition to cogni-
tive or affective processes like self-efficacy expectancy
[57], general implementation processes and implementa-
tion fidelity [58-60] should also be evaluated.
Conclusions
Our study demonstrated that the implementation of med-
ical innovations like the reported CHD treatment pathway
is influenced by multiple components. Besides reporting
the factors influencing the pathway implementation and
giving practical implications how to improve pathwayimplementation, we proposed a theoretical framework by
arranging the findings in a multidimensional model and
thereby add innovative aspects to the already existing im-
plementation research. Fields scarcely investigated collect-
ively in Bismarck type of health care systems, like bottom-
up developed local pathways and the integration of pri-
mary and secondary care, are considered.
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